Delisting risk
CNSP · NASDAQ · Biotechnology

CNS Pharmaceuticals

Seeks to acquire or in-license neurology and oncology drug candidates.

$5.75
After-hours close+0.23 (+4.11%)
At close$5.52(+0.10%)
DateEstimateReportedSurprise
Nov 2026−$0.27
Aug 2026−$0.24−$0.38−58.3%
May 2026−$5.37−$7.30−35.9%
Mar 2026−$5.09−$5.090.0%
Nov 2025−$6.63−$5.76+13.1%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Feb 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Dec 2019
Jun 2019
Mar 2019
Dec 2018
Sep 2018
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 18, 2026−$0.27
Aug 12, 2026−$0.24−$0.38−58.3%
May 14, 2026−$5.37−$7.30−35.9%
Mar 31, 2026−$5.09−$5.090.0%
Nov 14, 2025−$6.63−$5.76+13.1%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 14, 2025
May 15, 2025
Mar 31, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Apr 1, 2024
Nov 14, 2023
Aug 14, 2023
May 15, 2023
Mar 31, 2023
Nov 10, 2022
Aug 12, 2022
May 16, 2022
Mar 3, 2022
Nov 12, 2021
Aug 13, 2021
May 14, 2021
Feb 12, 2021
Nov 12, 2020
Aug 10, 2020
May 15, 2020
Mar 12, 2020
Dec 20, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018